Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

v3.23.1
Stockholders' Equity - Additional Information (Details) - USD ($)
 1 Months Ended 2 Months Ended 3 Months Ended
Aug. 03, 2022
Aug. 01, 2022
May 31, 2022
Jan. 31, 2022
Feb. 28, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Subsidiary or Equity Method Investee [Line Items]                
Common stock, shares authorized   70,000,000       70,000,000   70,000,000
Preferred stock, shares authorized   30,000,000       30,000,000   30,000,000
Common stock, par value           $ 0.0001   $ 0.0001
Common stock, shares issued           10,996,404   10,955,904
Common stock per share         $ 9.00      
Gross proceeds from sale of common stock $ 9,093,830   $ 99,999   $ 2,373,561   $ 2,373,561  
Warrants exercise price, per share   $ 6.25            
Transaction costs     $ 0   $ 0      
Deemed dividend on warrant modification             $ (450,578)  
Warrants exercised, shares     394,501          
Cashless exercise at fair market value per share     $ 9          
Issuance of common shares upon cashless exercise of warrants, shares     315,601          
Stock options outstanding           7,217,915   6,545,628
Fair value assumptions, contractual term           7 years    
Exercise price percentage           110.00%    
Percentage of shares granted           10.00%    
Warrants and rights exercisable period   Jan. 23, 2023            
Class of warrant or right date from which warrants or rights expire   Jul. 27, 2027            
Warrants           $ 224,399   $ 245,341
Gain on remeasurement of warrant liability           (20,942)    
Black-Sholes Method                
Subsidiary or Equity Method Investee [Line Items]                
Risk free interest rate 2.82%              
Volatility rate 77.50%              
Fair value assumptions, contractual term 5 years              
Warrants $ 343,735              
Gain on remeasurement of warrant liability           $ 20,942    
January 1 to January 26, 2022                
Subsidiary or Equity Method Investee [Line Items]                
Common stock, par value           $ 8.87    
January 27 to March 31, 2022                
Subsidiary or Equity Method Investee [Line Items]                
Sale of common stock, price per share           $ 9    
Maximum                
Subsidiary or Equity Method Investee [Line Items]                
Fair value assumptions, contractual term           10 years    
Warrants to purchase aggregate of common stock   100,000            
2018 Stock Option Plan                
Subsidiary or Equity Method Investee [Line Items]                
Common stock reserved for issuance           0    
Stock options outstanding           1,924,500    
Amended and Restated 2020 Equity Incentive Plan                
Subsidiary or Equity Method Investee [Line Items]                
Common stock reserved for issuance           0    
Stock options outstanding           3,983,023    
2021 Equity Incentive Plan                
Subsidiary or Equity Method Investee [Line Items]                
Common stock reserved for issuance   1,909,518       599,126    
Stock options outstanding           1,310,392    
IPO                
Subsidiary or Equity Method Investee [Line Items]                
Common stock, shares issued   219,872            
Number of common stock sold   2,000,000            
Issuance of common shares, value   $ 1,099,360            
Common stock per share   $ 5.00     $ 5.00      
Gross proceeds from common stock   $ 10,000,000            
Number of warrants exercise   20,520            
Warrants exercise price, per share   $ 5.00            
Overallotment Option                
Subsidiary or Equity Method Investee [Line Items]                
Number of common stock sold 300,000              
Common stock per share $ 5.00              
Gross proceeds from common stock $ 1,500,000              
Overallotment Option | Maximum                
Subsidiary or Equity Method Investee [Line Items]                
Class of warrant or right additional purchase aggregate of common stock 15,000              
Common Stock                
Subsidiary or Equity Method Investee [Line Items]                
Number of common stock sold     11,111   263,729      
Sale of common stock, price per share     $ 9   $ 9.00      
Issuance of common shares upon exercise of warrants, Shares     153,000 61,111     61,111  
Proceeds from issuance of common stock upon exercise of warrants     $ 275,400 $ 110,000        
Founder                
Subsidiary or Equity Method Investee [Line Items]                
Stock compensation expense             $ 52,500  
Restricted Stock Awards                
Subsidiary or Equity Method Investee [Line Items]                
Stock compensation expense           $ 164,070    
Shares granted           40,500    
Unvested shares           0    
Restricted Stock Awards | Founder                
Subsidiary or Equity Method Investee [Line Items]                
Shares granted             29,168  
MAIA Stock Warrants                
Subsidiary or Equity Method Investee [Line Items]                
Warrant modification, value       $ 144,497        
Deemed dividend on warrant modification             $ 450,578  
Stock Options                
Subsidiary or Equity Method Investee [Line Items]                
Risk free interest rate             2.14%  
Weighted-average grant date fair value           $ 3.27 $ 5.78  
Unrecognized compensation           $ 5,097,294    
Unrecognized compensation expense, recognized period           3 years 3 months 18 days    
Stock Options | Maximum                
Subsidiary or Equity Method Investee [Line Items]                
Fair value assumptions, contractual term           6 years 29 days 6 years 3 months  
Stock Options | Minimum                
Subsidiary or Equity Method Investee [Line Items]                
Fair value assumptions, contractual term           5 years 5 years